Impact of SARS‐CoV‐2 pandemic on pulmonary hypertension out‐patient clinics in Germany: a multi‐centre study

Yogeswaran, Athiththan; Gall, Henning; Tello, Khodr; Grünig, Ekkehard; Xanthouli, Panagiota; Ewert, Ralf; Kamp, Jan C.; Olsson, Karen M.; Wissmüller, Max; Rosenkranz, Stephan; Klose, Hans; Harbaum, Lars; Lange, Tobias; Opitz, Christian; Waelde, Andrea; Milger, Katrin; Sommer, Natascha; Seeger, Werner; Ghofrani, Hossein Ardeschir; Richter, Manuel J.

doi:10.1177/2045894020941682

Cited by 16 publications

(26 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another factor that might have resulted in poor outcomes in our series is the substantial disruptive impact that the pandemics had over the general operations of the pulmonary hypertension center, with less clinical evaluations, less diagnostic testing, and less therapeutic interventions [ 11 , 15 , 16 , 17 ]. The pandemic also could have contributed to the patients’ reluctance to seek medical attention, consistent with a long duration (mean of 12 days, median of 14 days) of COVID-19 symptoms prior to presentation.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City

et al. 2021

View full text Add to dashboard Cite

Information on outcomes of COVID-19 in pulmonary arterial hypertension (PAH) patients is limited to a few case series and surveys. Here, we describe our experience at a large Pulmonary Hypertension Center in New York City at the height of the pandemic. We performed a retrospective chart review of eleven consecutive PAH patients who were diagnosed with SARS-CoV-2 infection. We analyzed demographics, PAH severity, risk factors for COVID-19, and COVID-19 severity and outcomes. We found in our sample that 63.6% of patients required intensive care, and there was a 45.45% overall mortality. Most patients had a known COVID-19 contact and mean duration of symptoms prior to presentation was 12 days. Only 4/11 (36%) patients presented to a center with pulmonary hypertension expertise, all of whom survived. Most patients had at least moderate pulmonary hypertension with an average REVEAL score of 7.81 despite double or triple PAH therapy. Our cases series underscores the gravity of SARS-CoV-2 infection in patients with PAH. It also suggests possible interventions to prevent unfavorable outcomes such as preserving social distancing, PAH management optimization, and early and preferential presentation to a center with specialized expertise in PAH.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City

et al. 2021

View full text Add to dashboard Cite

show abstract

“…All these interventions should also have a positive effect on mental wellbeing accompanied by less anxiety and depressive symptoms [ 37 , 38 ]. Of note, scheduling of appointments of PH patients in specialized outpatient PH expert centers was significantly reduced during the lockdown period [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic

Dobler

Krüger

Strahler

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

The aim of the study was to analyze the effect of personal restrictions on physical activity, mental health, stress experience, resilience, and sleep quality in patients with pulmonary hypertension (PH) during the “lockdown” period of the COVID-19 pandemic. In total, 112 PH patients and 52 age-matched healthy control subjects completed a questionnaire on the topics of physical activity, mental health, resilience, and sleep quality. PH patients had significantly lower physical activity, mental health, and sleep quality compared to age-matched healthy controls. Physical activity positively correlated with mental health and sleep quality in the PH group. Mental wellbeing and life satisfaction could be predicted by total physical activity, sleep, stress level, and resilience. PH patients appeared as an especially vulnerable group, demanding interventions to promote an active lifestyle and protect mental health in these patients. This could be helpful in counseling on how to carry out physical activity while maintaining infection control.

show abstract

“…Before the COVID-19 pandemic, <10% of PH centers in the United States provided virtual visits, but now 97% of PH centers offer routine virtual visits [ 3 ]. The data from international PH registries (Australian and New Zealand [ 40 ], the United Kingdom [ 41 ], and Germany [ 42 ]) suggest that during the SARS-CoV-2 pandemic, there is a delay in referral and a subsequent impact on outcomes in children and adults with PH. While the COVID-19 pandemic is unfolding, the effect of co-infection of SARS-CoV-2 and influenza (COVI-Flu) will soon be devastating.…”

Section: Impact Of Covid-19 On Ph Care In Childrenmentioning

confidence: 99%

COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?

Das

2020

Medicina

View full text Add to dashboard Cite

The interplay between coronavirus disease 2019 (COVID-19) and pulmonary hypertension (PH) in children is unknown. Adults with PH are at potential risk for severe complications and high mortality due to associated comorbidities. It is difficult to extrapolate the outcomes of COVID-19 in adults to pediatric PH patients. Overall, a small number of COVID-19 cases is reported in patients with preexisting PH. Several factors may be responsible for the low incidence of COVID-19 in children with PH. Pulmonary hypertension is a rare disease, testing is not universal, and patients may have followed more rigorously the Center for Disease Control’s guidelines recommended for personal protection with mask-wearing, social distancing, and hand sanitization through ongoing health education. The small number of COVID-19 cases in patients with preexisting PH does not support that PH is protective for COVID-19. However, medications used to treat PH may have some protection against COVID-19. This review discusses the pathophysiology of PH occurring with COVID-19, differences between children and adults with COVID-19, strategies for management of preexisting PH in children during the ongoing pandemic, and its impact within the field of PH.

show abstract

Impact of SARS‐CoV‐2 pandemic on pulmonary hypertension out‐patient clinics in Germany: a multi‐centre study

Cited by 16 publications

References 10 publications

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City

COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City

Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic

COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far?

Contact Info

Product

Resources

About